Physician profile
Charley Beck
NPI 1871255315
$1,626.90
in general payments reported to CMS, 2019-2025
16 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.79 |
| Education | $225.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $260.50 | 2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $258.40 | 2025 | Dupixent |
| Genzyme Corporation | $219.64 | 2025 | |
| Incyte Corporation | $211.72 | 2025 | Opzelura, Opzelura |
| Abbvie INC. | $189.01 | 2025 | |
| Novo Nordisk INC | $145.70 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Leo Pharma INC. | $46.97 | 2025 | Anzupgo, Adbry |
| Pfizer INC. | $41.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $36.36 | 2025 | |
| Sunovion Pharmaceuticals INC. | $29.25 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $25.36 | 2022 | |
| Organon LLC | $24.84 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $24.83 | 2025 | |
| Botanix Sb INC | $16.28 | 2025 | Sofdra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $16.06 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charley Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.